It was reported that the blood spilled over the membrane onto the plasma side (filtrate side) of bc 140 plus.It occurred during patient use.The customer change the product and used a new one.No harm to any person was reported.The product was investigated in the getinge laboratory.A hemoconcentrator bc 140 was delivered.On the filtrate side of the hemoconcentrator, blood residues between the fibres could be confirmed.No damaged or loose fibres could be detected from the outside.Based on the investigation the failure can be confirmed.The bc140 is produced at an external supplier.Therefore, for further investigation scar was initiated.The supplier was informed about this complaint and scar.If significant information becomes available, we will initiate further steps.More information was requested in regards to the pressure values, blood and filtrate flow values.However, getinge representative confirmed that the customer can no longer answer our questions and the team of perfusionists is very experienced and uses this hemoconcentrator very often and so far they have not had any failures.The production history record (dhr) of the affected p-0400# with lot # 3000235012 was reviewed.According to the dhr results, the product p-0400# passed the defined manufacturing and final release specifications.There is no indication on manufacturing issues.Thus production related influences are unlikely.The exact cause of the failure could not be determined.The occurrence rate was calculated for the reported failure and product and it was determined that this is not a systemic issue.Therefore, no remedial action is required.The occurrence rate related to the reported issue is currently being monitored as part of maquet cardiopulmonary¿s trending program and additional investigations or corrections will be implemented in case of adverse trending.
|